ABOUT DATEN CAPITAL LLP

Founded in 2018, DATEN CAPITAL LLP is a healthcare-focused firm, leveraging data science to drive decision making. The firm will initially focus on the biotech sector, primarily in the US and Europe. Daten’s edge in biotech is driven by exclusive industry data and analytics, from Molecular Health GmbH, allowing DATEN to estimate drug trial success probabilities with an accuracy previously unimaginable. The firm is backed by leading corporates and investors in the healthcare and technology sectors.

INTERVIEW WITH DATEN'S FOUNDER

INTRODUCTION TO MOLECULAR HEALTH GmbH

Molecular Health was founded in 2004, by Friedrich von Bohlen, PhD with seed capital from Dievini Hopp Biotech (an investment vehicle of SAP Founder and ex-CEO Dietmar Hopp)

10+ years: Investment in deep in-silico research and development.

€150mn Invested capital in total, since 2004

Dietmar Hopp

Anchor investor, SAP Founder and ex-CEO

Friedrich von Bohlen

MH Founder and CEO

INTERVIEW WITH MOLECULAR HEALTH'S FOUNDER

Molecular Health Core Capabilities

CURRENT – COMPLETE – COMPREHENSIVE BIOMEDICAL KNOWLEDGE
  • Capturing
  • Integration
  • Curation
  • Contextualization
  • Referencing
  • Analytics
  • 105+ Employees
    89% Academics
    42% PhDs/MDs

    MILESTONES

    2004

    Co-Founded by friedrich Bohlen

    2005

    Dietmar hopp becomes major anchor investor

    2005/2007

    Strategic partnership with MD Andreson Cancer Center(MDACC), Houston, Tx

    2007

    Begin developing commercial software products

    2012

    FDA becomes partner for Drug safety information

    2014

    ISO 13485 QMS certification for medical Device Manufactures (MD 609736)

    2015

    Registration of molecular Health MH Guide as a general IVD in Europe

    2016

    Market introduction of MH Guide 2.0 for Hospital and Lab Providers

    2017

    Dataome® for Pharma

    2018

    MH Predict for Daten Capital’s exclusive use in the financial markets